株式会社極東書店トップ ＞ 商品一覧 ＞ Methodologies in Biosimilar Product Development.
商品詳細
Methodologies in Biosimilar Product Development.
・ISBN 978-0-367-89634-8 hard GB£ 210.00
￥66,528.- (税込) ※（※）価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。
電子版あり 大学・学術機関向け電子ブック（eBook）ISBN 978-1-003-20580-7
| 著者・編者 | Lee, Sang Joon / Chow, Shein-Chung (eds.), |
|---|---|
| シリーズ | Chapman & Hall/CRC Biostatistics Series |
| 出版社 | (Chapman & Hall/CRC, UK) |
| 出版年月 | 2021 |
| ページ数 | 380 pp. |
| 言語 | ENG |
| ニュース番号 | ＜M25-4131＞ |
解説
Methodologies for Biosimilar Product Development covers the practical and challenging issues that are commonly encountered during the development, review, and approval of a proposed biosimilar product. These practical and challenging issues include, but are not limited to the mix-up use of interval hypotheses testing (i.e., the use of TOST) and confidence interval approach, a risk/benefit assessment for non-inferiority/similarity margin, PK/PD bridging studies with multiple references, the detection of possible reference product change over time, design and analysis of biosimilar switching studies, the assessment of sensitivity index for assessment of extrapolation across indications without collecting data from those indications not under study, and the feasibility and validation of non-medical switch post-approval.
Key Features:
- Reviews withdrawn draft guidance on analytical similarity assessment.
- Evaluates various methods for analytical similarity evaluation based on FDA's current guidelines.
- Provides a general approach for the use of n-of-1 trial design for assessment of interchangeability.
- Discusses the feasibility and validity of the non-medical switch studies.
- Provides innovative thinking for detection of possible reference product change over time.
This book embraces innovative thinking of design and analysis for biosimilar studies, which are required for review and approval of biosimilar regulatory submissions.